About: Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
Creator	Giacconi, Robertina Malavolta, Marco Brunetti, Dario Maggi, Fabrizio Provinciali, Mauro
Source	Medline; PMC
abstract	The higher death rate caused by COVID-19 in older people, especially those with comorbidities, is a challenge for biomedical aging research. Here we explore the idea that an exacerbated inflammatory response, in particular that mediated by IL-6, may drive the deleterious consequences of the infection. Data shows that other RNA viruses, such as influenza virus, can display enhanced replication efficiency in senescent cells, suggesting that the accumulation of senescent cells with aging and age-related diseases may play a role in this phenomenon. However, at present, we are completely unaware of the response to SARS-CoV and SARS-COV-2 occurring in senescent cells. We deem that this is a priority area of research because it could lead to the development of several therapeutic strategies based on senotherapeutics or prevent unsuccessful attempts. Two of these senotherapeutics, azithromycin and ruxolitinib, are currently undergoing testing for their efficacy in treating COVID-19. The potential of these strategies is not only for ameliorating the consequences of the current emergence of SARS-CoV-2, but also for the future emergence of new viruses or mutated ones for which we are completely unprepared and for which no vaccines are available.
has issue date	2020-04-08(xsd:dateTime)
bibo:doi	10.3390/cells9040909
bibo:pmid	32276453
has license	cc-by
sha1sum (hex)	6f4f672adff81217f14147f9db0602c43507d80b
schema:url	https://doi.org/10.3390/cells9040909
resource representing a document's title	Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
has PubMed Central identifier	PMC7226793
has PubMed identifier	32276453
schema:publication	Cells
resource representing a document's body	covid:6f4f672adff81217f14147f9db0602c43507d80b#body_text
is schema:about of	named entity 'response' named entity 'mediated' named entity 'completely' named entity 'NEW' named entity 'CHALLENGE' named entity 'PEOPLE' named entity 'senescent cells' named entity 'Two' named entity 'current' named entity 'comorbidities' named entity 'However' named entity 'development' named entity 'treating' named entity 'Data' named entity 'idea' named entity 'vaccines' named entity 'testing' named entity 'completely' named entity 'inflammatory response' named entity 'viruses' named entity 'ruxolitinib' named entity 'senescent cells' named entity 'COVID' named entity 'IL-6' named entity 'COVID' named entity 'The higher' named entity 'cell death' named entity 'p21' named entity 'chronic obstructive pulmonary disease' named entity 'chronic inflammation' named entity 'mitochondrial' named entity 'chronic inflammation' named entity 'innate immune signaling' named entity 'mitochondria' named entity 'IFVs' named entity 'hypertension' named entity 'infection' named entity 'viral replication' named entity 'infection' named entity 'human immunodeficiency virus-1' named entity 'mammalian target of rapamycin' named entity 'lung' named entity 'senescent cell' named entity 'SARS-CoV-2' named entity 'senescent cells' named entity 'human-to-human' named entity 'dipeptidyl peptidase 4' named entity 'lung' named entity 'probability' named entity 'antiviral' named entity 'GRP78' named entity 'mitochondrial' named entity 'senescence' named entity 'senescent cells' named entity 'cellular senescence' named entity 'Coronaviruses' named entity 'CMV' named entity 'IFV' named entity 'Drp1' named entity 'therapeutic strategies' named entity 'aging research' named entity 'inflammation' named entity 'kidney' named entity 'pulmonary fibrosis' named entity 'senescent cells' named entity 'Interleukin-6 receptor' named entity 'tumor cells' named entity 'pathological processes' named entity 'Necrosis' named entity 'Clinical Trial' named entity 'elderly patients' named entity 'senescent cells' named entity 'wild type' named entity 'simian virus 40' named entity 'SARS-CoV-2' named entity 'clinical trials' named entity 'Melatonin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software